Cell Genesys is focused on the development and commercialization of biological therapies for patients with cancer. The company is currently pursuing two clinical-stage product platforms — GVAX(R) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include GVAX immunotherapy for prostate cancer, GVAX immunotherapy for pancreatic cancer and leukemia, and a CG0070 oncolytic virus therapy for bladder cancer.